Champions Oncology Stock Performance
| CSBR Stock | USD 5.06 0.03 0.60% |
The firm shows a Beta (market volatility) of -0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Champions Oncology are expected to decrease at a much lower rate. During the bear market, Champions Oncology is likely to outperform the market. Champions Oncology has an expected return of -0.31%. Please make sure to confirm Champions Oncology potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Champions Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Champions Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in May 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.15 | Five Day Return 0.75 | Year To Date Return (11.25) | Ten Year Return (52.42) | All Time Return (28.63) |
Last Split Factor 1:12 | Last Split Date 2015-08-12 |
1 | Champions Oncology to Unveil Q3 Results, Host Conference Call on March 12, 2024 - BNN Breaking | 03/06/2024 |
2 | Champions Oncology Reports Quarterly Revenue of 12.0 Million | 03/12/2024 |
3 | Craig-Hallum downgrades Champions Oncology stock to hold amid market headwinds | 03/13/2024 |
4 | Champions Oncology, Inc. Q3 2024 Earnings Call Transcript | 03/19/2024 |
5 | Acquisition by Scott Tobin of 10000 shares of Champions Oncology at 3.21 subject to Rule 16b-3 | 03/26/2024 |
6 | Acquisition by Brady Davis of 135000 shares of Champions Oncology at 6.5 subject to Rule 16b-3 | 04/01/2024 |
7 | Disposition of 34375 shares by Daniel Mendelson of Champions Oncology at 5.76 subject to Rule 16b-3 | 04/03/2024 |
8 | Acquisition by Daniel Mendelson of 500 shares of Champions Oncology at 5.83 subject to Rule 16b-3 | 04/12/2024 |
9 | Will Champions Oncology Spend Its Cash Wisely | 04/17/2024 |
| Begin Period Cash Flow | 9 M | |
| Total Cashflows From Investing Activities | -2.9 M |
Champions |
Champions Oncology Relative Risk vs. Return Landscape
If you would invest 626.00 in Champions Oncology on January 26, 2024 and sell it today you would lose (123.00) from holding Champions Oncology or give up 19.65% of portfolio value over 90 days. Champions Oncology is currently does not generate positive expected returns and assumes 2.7496% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Champions, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Champions Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Champions Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Champions Oncology, and traders can use it to determine the average amount a Champions Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSBR |
Estimated Market Risk
| 2.75 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Champions Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Champions Oncology by adding Champions Oncology to a well-diversified portfolio.
Champions Oncology Fundamentals Growth
Champions Stock prices reflect investors' perceptions of the future prospects and financial health of Champions Oncology, and Champions Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Champions Stock performance.
| Return On Equity | -3.89 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 71.65 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 6.77 X | ||||
| Price To Sales | 1.38 X | ||||
| Revenue | 53.87 M | ||||
| Gross Profit | 24.34 M | ||||
| EBITDA | (1.4 M) | ||||
| Net Income | (5.33 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 8.6 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | (0.15) X | ||||
| Cash Flow From Operations | 3.96 M | ||||
| Earnings Per Share | (0.72) X | ||||
| Market Capitalization | 68.92 M | ||||
| Total Asset | 34.31 M | ||||
| Retained Earnings | (77.32 M) | ||||
| Working Capital | (2.28 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
About Champions Oncology Performance
To evaluate Champions Oncology Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Champions Oncology generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Champions Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Champions Oncology market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Champions's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.000012 | 0.000014 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (1.32) | (1.39) |
Things to note about Champions Oncology performance evaluation
Checking the ongoing alerts about Champions Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Champions Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Champions Oncology generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 53.87 M. Net Loss for the year was (5.33 M) with profit before overhead, payroll, taxes, and interest of 24.34 M. | |
| About 26.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Will Champions Oncology Spend Its Cash Wisely |
- Analyzing Champions Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Champions Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Champions Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Champions Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Champions Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Champions Oncology's stock. These opinions can provide insight into Champions Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.Note that the Champions Oncology information on this page should be used as a complementary analysis to other Champions Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Champions Stock analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Champions Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.72) | Revenue Per Share 3.634 | Quarterly Revenue Growth (0.06) | Return On Assets (0.17) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.